OraSure Technologies (NASDAQ:OSUR) Raised to Hold at Wall Street Zen

OraSure Technologies (NASDAQ:OSUR) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Monday.

Separately, Weiss Ratings raised shares of OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $3.00.

OraSure Technologies Trading Down 3.0%

Shares of OSUR stock opened at $3.88 on Monday. OraSure Technologies has a 12 month low of $2.08 and a 12 month high of $4.58. The stock has a market cap of $267.60 million, a P/E ratio of -5.62 and a beta of 1.00. The company has a 50 day simple moving average of $4.16 and a two-hundred day simple moving average of $3.45.

Insider Activity

In related news, Director Steven Kyle Boyd acquired 25,000 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The stock was bought at an average cost of $2.99 per share, for a total transaction of $74,750.00. Following the purchase, the director owned 113,462 shares in the company, valued at $339,251.38. The trade was a 28.26% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 4.70% of the company’s stock.

Hedge Funds Weigh In On OraSure Technologies

Several large investors have recently added to or reduced their stakes in OSUR. Nierenberg Investment Management Company LLC bought a new position in shares of OraSure Technologies in the second quarter worth approximately $247,775,000. Diversify Advisory Services LLC bought a new stake in shares of OraSure Technologies during the 2nd quarter valued at $47,000. BlackRock Inc. purchased a new position in shares of OraSure Technologies during the 2nd quarter valued at $27,905,000. Deutsche Bank AG purchased a new position in shares of OraSure Technologies during the 2nd quarter valued at $527,000. Finally, OneDigital Investment Advisors LLC purchased a new position in shares of OraSure Technologies during the 2nd quarter valued at $91,000. Hedge funds and other institutional investors own 93.50% of the company’s stock.

OraSure Technologies Company Profile

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.